An observational study in Unipolar Depression, Major Depressive Disorder (MDD) and Depression, sponsored by Emobot. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-22.
Sponsored by Emobot · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Depressive Disorder, Major with a site in France — 28 open to participants now, 31 under way, 2 of them phase 3. Depressive Disorder, Major · France.
Among the 127 studies in Depressive Disorder, Major with a site in France, this one is the 13th largest by planned enrollment of the 21 observational ones that give a count, is one of 10 that started in 2025, is one of 21 observational ones, reaches primary completion later than 5 of the 30 other live ones, and was the 118th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →28 of the 127 studies in Depressive Disorder, Major with a site in France are open now. Recruiting first, the newest first:
CHU de Reims · Sites in France
Ages 18–65 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+ · Healthy volunteers
Fondation FondaMental · Sites in France
Ages 15–60 · Healthy volunteers
Hospital Center Guillaume Régnier · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–65
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 10 · Phase 3 37 · Phase 4 10
First in 2003; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 98 is below the median of 132 across 403 observational studies indexed under Depressive Disorder, Major.
Median enrollment 232 across the 106 interventional studies, 128 across the 21 observational. Of the 84 that completed or were terminated, 31 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 127 have an industry lead sponsor. The 10 most frequent:
Emobot is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Emobot has 3 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
8 of the studies in Depressive Disorder, Major with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07316803Centre hospitalier de Ville-Evrard, FranceGroup Intervention for Romantic Relationships in Young Adults With Severe Mental Illness | 2026-11-30 |
| NCT06234176Centre Hospitalier EsquirolImpact of Psychomotor Therapy on the Quality of Life in Depression | 2027-02 |
| NCT06601140EmobotEvaluation of the Concordance Between Measures Obtained by a Medical Device for Emotional Monitoring (EMOCARE) and the Patient Health Questionnaire (PHQ-9) Score in Patients With Mild to Severe Depressive Episode | 2027-02-04 |
| NCT06732284Centre Hospitalier Universitaire de NīmesStudy of Sleep Inertia in Major Depressive Disorder by the Psychomotor Vigilance Task | 2027-03 |
Add all 8 to your calendar (.ics) → With an account.
Among the 127 studies in Depressive Disorder, Major with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to validate the EmoDTx as a digital tool for mood monitoring in adult patients with unipolar depression. The study is prospective, multicenter, and observational, with a single-arm approach. The device studied, EmoDTx, is a mood-monitoring application that analyzes patients' facial expressions to assess their emotional state. The study aims to compare mood scores obtained via EmoDTx with those of standard depression questionnaires (MADRS, PHQ-9, BDI-II, HAMD-17, QIDS-SR16). It will also provide information on how patients feel about the use of passive monitoring software (without the active involvement of the patient) and how the feedback sent to patients can help in their care.
Participants who agree to take part in the study, during a selection visit, will be able to:
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
This study's planned enrollment of 98 is below the median of 132 across 403 observational studies indexed under Depressive Disorder, Major.
Browse Depressive Disorder, Major studies →Emobot is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Compared within Depressive Disorder, Major, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Depressive Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adult patients suffering from mild to severe unipolar depression
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Patients with a to the device under evaluation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Change of score EmoDTx
Absolute difference
Time frame: From baseline to 4 weeks
Change of score MADRS administrated by an investigator
Absolute difference
Time frame: From baseline to 4 weeks
Change of EmoDTx score
Time frame: Between 2 weeks and 6 weeks
Change of score PHQ-9 self reported
Time frame: Between 2 weeks and 6 weeks
Change of EmoDTx score
Time frame: Between Baseline and 4 weeks, between Baseline and 8 weeks and between 4 weeks and 8 weeks
Change of HAMD-17 questionnaire administered by the investigator
Time frame: Between Baseline and 4 weeks, between Baseline and 8 weeks and between 4 weeks and 8 weeks
Change of EmoDTx score
Time frame: between Baseline and 4 weeks - between Baseline and 8 weeks - between 4 weeks and 8 weeks
Change of score QIDS- SR16 self administrated
Time frame: between Baseline and 4 weeks - between Baseline and 8 weeks - between 4 weeks and 8 weeks
Change of score BDI-II self administrated
Time frame: between Baseline and 4 weeks - between Baseline and 8 weeks - between 4 weeks and 8 weeks
Score EmoDTx
Time frame: At 4-weeks, at 8 week
Score MADRS administrated by the investigator
Time frame: At 4-weeks, at 8 week
Score HAMD-17 administrated by the investigator
Time frame: At 4-weeks, at 8 week
Score PHQ-9 self administrated
Time frame: At 2-weeks and 6 weeks.
Score QIDS-SR16 self administrated
Time frame: At 4-weeks and 8 weeks
To evaluate the ability of EmoDTx to predict changes in patient's mood earlier than the standard-of-care questionnaires HAMD-17, within 4 weeks and 8 weeks of follow-up.
Time frame: Time to detection by EmoDTx of changes to depression severity symptoms within 4 weeks and 8 weeks of follow-up as compared to changes detected by standard-of-care questionnaires HAMD-17 Changes in depression severity
To evaluate the ability of EmoDTx to predict changes in patient's mood earlier than the standard-of-care questionnaires MADRS, within 4 weeks and 8 weeks of follow-up.
Time frame: Time to detection by EmoDTx of changes to depression severity symptoms within 4 weeks and 8 weeks of follow-up as compared to changes detected by standard-of-care questionnaires MADRS Changes in depression severity
Score EQ-5D-5L
Time frame: At 4 weeks and 8 weeks
Change of EmoDTx score when feedback is deactivated
Time frame: From baseline to 4 weeks
Change of EmoDTx score when feedback is activated
Time frame: From 4 weeks to 8 weeks
Acceptability of medical device questionnaire
Time frame: A baseline and 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2025, 4 months after the start.
Of 29 industry-sponsored observational studies under Depressive Disorder, Major, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 33. This study's planned 4 months is below that.
Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Emobot